[1]Planchard D, et al. J Thorac Oncol. 2022 Jan;17(1):103-115.[2]Planchard D. et al, Lancet Oncol 2017; 18: 1307–16.[3]MOK T S,WU Y L,THONGPRASERT S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361( 10) : 947-957. DOI: 10.1056/ NEJMoa0810699.[4]ZHOU C C,WU Y L,CHEN G Y,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer ( OPTIMAL,CTONG-0802) : a multicentre,open-label,randomised,phase 3 study[J]. Lancet Oncol,2011,12( 8) : 735- 742. DOI: 10.1016/ S1470-2045( 11) 70184-X.[5]Yi-Long Wu, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 1454-66.[6]Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018;36(22):2244-2250.[7]Jean-Charles Soria, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018; 378: 113-125.[8] Suresh S. Ramalingam, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020; 382: 41-50.[9]TSENG J S,SU K Y,YANG T Y,et al. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M [J]. Oncotarget,2016,7( 30) : 48059- 48069. DOI: 10. 18632/oncotarget.10351.[10] CROSS D A E,ASHTON S E,GHIORGHIU S,et al. AZD9291,an irreversible EGFR TKI,overcomes T790Mmediated resistance to EGFR inhibitors in lung cancer[J]. Cancer Discov,2014,4( 9) : 1046-1061. DOI: 10. 1158/ 2159-8290.CD-14-0337.[11]WU S G,SHIH J Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer,2018,17( 1) : 38. DOI: 10.1186/ s12943-018-0777-1[12] Ota T,Okabayashi A,Fukuoka M.Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma Respirol Case Rep. 2021 Aug 30;9(10):e0841. MCC码TML0018538-48292;素材生效日2024.03.07;素材失效日2025.03.07* 此文仅用于向医学人士提供科学信息,不代表本平台观点更多医疗资讯,点击“阅读原文”查看